Aggregating data and transforming it into actionable knowledge has the power to play a profound role in improving therapies and the overall daily management of the disease, resulting in better glucose control, health outcomes and quality of life. With this funding initiative, the Trust will consider new and advanced projects including, but not limited to, mobile platforms and applications, electronic medical records and electronic health records, embedded wireless sensors and communications, and big data analytics. Integration with consumer, patient and healthcare professional devices and platforms will likely be essential.
Over the past decade, advances in medical device technologies have made a significant impact on the monitoring, management and treatment of T1D. However, data from the T1D Exchange demonstrates that, due to the complexity of the disease, the majority of people with T1D are not achieving optimal health outcomes despite today’s tools, and many report feeling overwhelmed by information on insulin dosing, blood glucose values, exercise, meals and other sources.
Timeline:
- Funding Opportunity Release Date - June 1, 2015
- LOI Submission Deadline – July 20, 2015
- Selected Applicants Proceed to Full Proposal - August 2015
- Full Proposal Submission Deadline - October 5, 2015
- Anticipated Commencement of Selected Programs - First Quarter, 2016
More information about the Diabetes Data Innovation Initiative and the related request for proposals can be found on the Trust’s website at www.helmsleytrust.org/diabetes-data-innovation-initiative.
About the Helmsley Charitable Trust
The Leona M. and Harry B. Helmsley Charitable Trust aspires to improve lives by supporting exceptional nonprofits and other mission-aligned organizations in health, selected place-based initiatives, and education and human services. Since 2008, when the Trust began its active grantmaking, it has committed more than $1 billion. The Helmsley Type 1 Diabetes Program is the largest private foundation funder of T1D in the United States focused on understanding the disease, developing better treatments and improving care and access.